Plasma levels of clozapine and norclozapine in Mexican schizophrenia patients

Abstract

The aim of the present study was to determine the prescribing practice for clozapine (CAS 5786-21-0) as well as the plasma levels of clozapine and its main metabolite norclozapine (CAS 6104-71-8) in Mexican patients. A prospective study was performed in 69 in and out psychotic patients taking clozapine. Blood samples were taken at steady state. Plasma concentrations of clozapine and norclozapine were determined by HPLC. The results showed that the mean daily dose administered was 250 mg/d. Plasma levels showed a large interindividual variability. Mean plasma levels were 411.3 ± 328.12 ng/mL, for clozapine and 172.0 ± 129.9 ng/mL for norclozapine. When data were compared with those reported in other populations, it was found that although the dose was lower than that reported in Caucasians, the plasma levels were similar. As a result, the predictive models for the estimation of clozapine concentration in Caucasians were not appropriate for application in Mexican patients. The findings suggest ethnic differences in the ratio dose/plasma levels of clozapine in Mexican patients. Further studies are required to expand the observations.

Key words

Clozapine - Mexican patients - Norclozapine - Plasma levels - Schizophrenia

• References

• 1 Zafar A, Sharif MD. Pharmacokinetics, metabolism, and drug-drug interactions of atypical antipsychotics in special populations. Primary Care Companion. J Clin Psychiatry. 2003; 5: 22-5
• 2 Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine induced agranulocytosis.. Incidence and risk factors in the United States N Eng J Med. 1993; 329: 162-7
• 3 Ulrich S, Baumann B, Wolf R, Lehmann D, Peters B, Bogerts B et al Therapeutic drug monitoring of clozapine and relapse–a retrospective study of routine clinical data. Int J Clin Pharmacol Ther. 2003; Jan 41 (1) 3-13
• 4 Tang YL, Mao P, Li FM, Li W, Chen Q, Jiang F et al Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. Br J Clin Pharmacol. 2007; Jul 64 (1) 49-56
• 5 Subramaniam M, Ng CH, Chong SA, Mahendran R, Lambert T, Pek E et al Metabolic differences between Asian and Caucasian patients on clozapine treatment. Hum Psychopharmacol. 2007; Jun 22 (4) 217-22
• 6 Lee ST, Ryu S, Nam HJ, Lee SY, Hong KS. Determination of pharmacokinetic properties of clozapine and norclozapine in Korean schizophrenia patients. Int Clin Psychopharma col. 2009; May 24 (3) 139-44
• 7 Spina E, Avenoso A, Facciolà G, Fabrazzo M, Monteleone P, Maj M et al. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol. 1998; 13: 141-5
• 8 Liu HC, Chang WH, Wei FC, Lin SK, Jann MW. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit. 1996; 18: 200-7
• 9 Chang WH, Lin SK, Lane HY, Hu WH, Jann MW, Lin HN. Clozapine dosages and plasma drug concentrations. J For mos Med Assoc. 1997; Aug 96 (8) 599-605
• 10 Edno L, Combourieu I, Cazenave M, Tignol J. Assay for quantitation of clozapine and its metabolite N-desmethylclozapine in human plasma by high-performance liquid chromatography with ultraviolet detection. J Pharm Biomed Anal. 1997; 16: 311-8
• 11 Aymard N, Viala A, Baldacci C, Smagghe PO, Vacheron MN, Caroli F. Pharmacoclinical strategy in neuroleptic resistant schizophrenic patients treated by clozapine: clinical evolution, concentration of plasma and red blood cell clozapine and desmethylclozapine, whole blood serotonin and tryptophan. Prog Neuropsychopharmacol Biol Psychiatry. 1999; Jan 23 (1) 25-41
• 12 Hussein R, Gad A, Raines DA, Chaleby K, Al-Rawithi S, El-Yazigi A. Steady-state pharmacokinetics of clozapine in refractory schizophrenic Saudi Arabian patients. Pharm Pharmacol Comm. 1999; 5: 473-8
• 13 Raggi MA, Bugamelli F, Mandrioli R, De Ronchi D, Volterra V. Development and validation of an HPLC method for the simultaneous determination of clozapine and desmethylclozapine in plasma of schizophrenic patients. Chromatographia. 1999; Jan 49 (1) 75-80
• 14 Llorca PM, Lancon C, Disdier B, Farisse J, Sapin C, Auquier P. Effectiveness of clozapine in neuroleptic-resistant schizophrenia: clinical response and plasma concentrations. J Psychiatry Neurosci. 2002; 27: 30-7
• 15 Wong JO, Leung S, Mak T, NG RM, Chan K, Cheung HH et al. Plasma clozapine levels and clinical response in treat ment-refractory Chinese schizophrenic patients. Prog Neu ropsychopharmacol Biol Psychiatry. 2006; March 30 (2) 251-64
• 16 Bergemann N, Abu-Tair F, Aderjan R, Kopitz J. High clozapine concentrations in leukocytes in a patient who developed leukocytopenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007; Jun 31 (5) 1068-71
• 17 Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to asses compliance in individual patients. J Clin Psychopharmacol. 2004; 24: 70-8
• 18 Perry PJ, Bever KA, Arndt S, Combs MD. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 1998; 44: 733-8
• 19 Centorrino F, Baldessarini RJ, Kando L, Frankenburg FR, Volpicelli SA, Puopolo PR et al. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. Am J Psychiatry. 1994; 151: 123-5
• 20 Palego L, Biondi L, Giannaccini G, Sarno N, Elmi S, Ciapparelli A et al. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients. Influence of patient-related variables. Prog Neuropsychopharmacol Biol Psychiatry. 2002; Apr 26 (3) 473-80
• 21 Ozdemir V, Kalow W, Posner P, Collins EJ, Kennedy JL, Tang BK et al. CYP1A2 activity as measured by caffeine test predicts clozapine and active metabolite norclozapine steady-state concentration in patients with schizophrenia. J Clin Psychopharmacol. 2001; Aug 21 (4) 398-407
• 22 Jaquenoud SE, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S et al. ABCB1 and Cytochrome P450 polymorphisms. Clinical pharmacogenetics of clozapine. J Clin Psychopharmacol. 2009; Aug 29 (4) 319-26
• 23 Taylor DM.. Prescribing of clozapine and olanzapine: dos age, polypharmacy and patient ethnicity. Psychiatr Bull. 2004; 28: 241-3
• 24 Ruiz P, Varner RV, Small DR, Johnson BA. Ethnic differences in the neuroleptic treatment of schizophrenia. Psychiatr Q. 1999; Summer 70 (2) 163-72
• 25 Frackiewicz EJ, Herrera JM, Sramek JJ, Collazo Y, Lawson WB. Risperidone in the treatment of Hispanic inpatients with schizophrenia: a pilot study. Psychiatry. 2002; 65: 371-4